Recent Updates
Recently added Catalysts

AZD9550

Phase 2

Obesity or Overweight | Small molecule | Metabolic |AstraZeneca PLC|Last Updated: Jun 3, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment377
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06862791A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AlonePHASE2 COMPLETED 377 — — Feb 18, 2025May 11, 2026Jun 3, 202653 United States, Australia +3
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent change in body weight from baseline after 36 weeks of treatment
36 weeks

To determine whether treatment with AZD9550 and AZD6234 in combination is superior to placebo for weight loss

Weight loss ≥ 5% from baseline after 36 weeks of treatment
36 weeks

To assess the effect of treatment with AZD9550 and AZD6234 in combination vs placebo on the proportion of participants with weight loss ≥ 5%

Secondary Endpoints
Absolute change in body weight from baseline after 36 weeks of treatment
36 weeks
Weight loss ≥ 5% from baseline after 36 weeks of treatment
36 weeks
Weight loss ≥ 10% and ≥ 15% from baseline after 36 weeks of treatment
36 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1EXPERIMENTALAZD9550 low dose + AZD6234 low dose or placebos
Arm 2EXPERIMENTALAZD9550 medium dose + AZD6234 medium dose or placebos
Arm 3EXPERIMENTALAZD9550 high dose + AZD6234 high dose or placebos
Arm 4EXPERIMENTALAZD9550 low dose + AZD6234 medium dose or placebos
Arm 5EXPERIMENTALAZD9550 medium dose + AZD6234 low dose or placebos
Arm 6EXPERIMENTALAZD9550 high dose + AZD6234 medium dose or placebos
Arm 7EXPERIMENTALAZD9550 medium dose + AZD6234 high dose or placebos
Arm 8EXPERIMENTALAZD9550 high dose or placebo
Arm 9EXPERIMENTALAZD6234 high dose or placebo
Interventions
NameTypeDescription
AZD9550DRUGIMP injected subcutaneous, once weekly. Unit dose strength as per CSP
AZD6234DRUGIMP injected subcutaneous, once weekly. Unit dose strength as per CSP.
Placebo comparatorDRUGPlacebo matching IMP dose injected subcutaneously, once weekly.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites53

Inclusion Criteria: * Participant must be 18 to 75 years of age inclusive. * BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity. * A stable, self-reported body weight for 3 months prior to screening. * Male and female participants: Contraceptive use by males or females shou...

Countries:United StatesAustraliaCanadaGermanyJapan
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
HIGHJun 4, 2026NCT06862791Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJun 4, 2026NCT06862791Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJun 4, 2026NCT06862791Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJun 4, 2026NCT06862791Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHJun 4, 2026NCT06862791Status: ACTIVE_NOT_RECRUITING → COMPLETED
LOWMay 26, 2026NCT06862791primaryCompletionDate: changed
LOWMay 24, 2026NCT06862791studyFirstPostDate: changed